Meeting
2020 Gastrointestinal Cancers Symposium
Impact of dose reductions on clinical outcomes among patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in oncology clinics in the United States.
Authors
Paul Cockrum
Ipsen Biopharmaceuticals, Cambridge, MA
Paul Cockrum , Andy Surinach , George P. Kim , Daniel Mercer , Jim M. Koeller , Rebecca A. Miksad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 665)
Abstract #
665
Poster Bd #
H18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
KRAS G12C-mutated pancreatic cancer: Clinical outcomes based on chemotherapeutic regimen.
First Author: Aaron Ciner
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Real-world clinical outcomes of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens: Impact of prior irinotecan (IRI) exposure.
First Author: Kenneth H. Yu
Poster
2017 Gastrointestinal Cancers Symposium
Analysis of outcomes in metastatic pancreatic cancer: Real-world experience in academic cancer centers.
First Author: Elizabeta C. Popa
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Assessment of circulating tumor DNA (ctDNA) burden and association with outcomes in metastatic gastric cancer (mGC) patients using real-world data (RWD).
First Author: Senaka A. Peter